Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

ClinicalTrials.gov ID: NCT00515086

Public ClinicalTrials.gov record NCT00515086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 7:28 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of RAD001 in Patients With Recurrent Glioblastoma Multiforme

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will define the safety and efficacy of Everolimus (RAD001) administered daily in patients with glioblastoma multiforme (GBM)

Study identification

NCT ID
NCT00515086
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
41 participants

Conditions and interventions

Interventions

Drug · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2007 (Type not available)
Primary completion
Aug 2009 (Actual)
Completion
Aug 2009 (Actual)
Last update posted
Sep 22, 2011

2007 – 2009

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
UCLA Los Angeles California 90095 —
Northwestern University Chicago Illinois 60611 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 —
Dana Farber Cancer Institute Boston Massachusetts 02115 —
Duke University - Preston Robert Tisch Brain Tumor Center Durham North Carolina 27710 —
University of Cincinnati Cincinnati Ohio 45219 —
Seattle Cancer Care Alliance Seattle Washington 98109 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00515086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 22, 2011 · Synced Nov 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00515086 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →